Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Relay Therapeutics, Inc.

NASDAQ: RLAY · Life Sciences · 7 alerts · CIK 1812364

Share price
$17.27Close, Nov 16
Market cap
$3.82B
Shares outstanding
220.96MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Relay Therapeutics, Inc. filings on SEC EDGAR ↗

4:17 PM ET 10-Q
Financial Results

Relay Therapeutics Q3 2026 Results: Net Loss of $81.7M, Loss Widens

Relay Therapeutics is a large accelerated filer with 220,959,470 shares of common stock outstanding as of October 30, 2026. The company remains a clinical-stage biopharmaceutical firm with no product revenue, incurring significant operating losses while focusing on the development of its precision medicine pipeline.

Key figure
Net loss $81.7M
4:11 PM ET 8-K
Financial Results

Relay Therapeutics Financial Results

Relay Therapeutics reported third quarter 2026 financial results, highlighting a cash position of approximately $849 million. The company provided clinical updates for its breast cancer and vascular anomalies programs, including an expected enrollment completion for the Phase 3 ReDiscover-2 trial in mid-2027.

Term
Q3 2026

“This quarter, we are very pleased by the pace of enrollment of our ReDiscover-2 trial for second-line breast cancer and also look forward to sharing updated ReInspire data for vascular anomalies at ASH. In addition, we continue to prepare for our frontline breast cancer trial testing the selective-selective combination of zovegalisib and atirmociclib, and we were highly encouraged by the data we saw from Pfizer’s FourLight-1 trial, which we believe showed the potential advantage of a CDK4-selective approach.”

Sanjiv Patel, M.D., President and Chief Executive Officer of Relay Therapeutics
4:18 PM ET Form 4
Insider Selling

Relay Therapeutics Insider Peter Rahmer Sells $14K of Stock

Peter Rahmer sold 753 shares of Relay Therapeutics, Inc. at $18.62 a share, worth $14K in total on Oct 28, 2026. Shares held after the trade: 222,904 (-0.3%).

Value
$14K
Shares
753
Price
$18.62
Holding change
-0.3%
Trade date
Oct 28, 2026
4:16 PM ET Form 4
Insider Selling

Relay Therapeutics President, R&D Donald A. Bergstrom Sells $41.9K of Stock

Donald A. Bergstrom, President, R&D, sold 2,252 shares of Relay Therapeutics, Inc. at $18.62 a share, worth $41.9K in total on Oct 28, 2026. Shares held after the trade: 396,878 (-0.6%).

Value
$41.9K
Shares
2,252
Price
$18.62
Role
President, R&D
Holding change
-0.6%
Trade date
Oct 28, 2026
4:15 PM ET Form 4
Insider Selling

Relay Therapeutics CFO Thomas Catinazzo Sells $27.4K of Stock

Thomas Catinazzo, CFO, sold 1,469 shares of Relay Therapeutics, Inc. at $18.62 a share, worth $27.4K in total on Oct 28, 2026. Shares held after the trade: 103,665 (-1.4%).

Value
$27.4K
Shares
1,469
Price
$18.62
Role
CFO
Holding change
-1.4%
Trade date
Oct 28, 2026
5:29 PM ET Form 4
Insider Selling

Relay Therapeutics President and CEO Sanjiv Patel Sells $872K of Stock

Sanjiv Patel, President and CEO, sold 48,199 shares of Relay Therapeutics, Inc. at $18.10 a share, worth $872K in total on Oct 7, 2026. Shares held after the trade: 471,301 (-9.3%).

Value
$872K
Shares
48,199
Price
$18.10
Role
President and CEO
Holding change
-9.3%
Trade date
Oct 7, 2026
5:29 PM ET Form 4
Insider Selling

Relay Therapeutics CFO Thomas Catinazzo Sells $325K of Stock

Thomas Catinazzo, CFO, sold 17,511 shares of Relay Therapeutics, Inc. at $18.58 a share, worth $325K in total on Oct 6, 2026. Shares held after the trade: 105,340 (-14.3%).

Value
$325K
Shares
17,511
Price
$18.58
Role
CFO
Holding change
-14.3%
Trade date
Oct 6, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.